- Home
- CLGN vs LVTX Comparison
CLGN vs LVTX Comparison
Compare CLGN & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- LVTX
- Stock Information
- Founded
- CLGN 2004
- LVTX 2016
- Country
- CLGN Israel
- LVTX Netherlands
- Employees
- CLGN N/A
- LVTX N/A
- Industry
- CLGN Industrial Specialties
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CLGN Health Care
- LVTX Health Care
- Exchange
- CLGN Nasdaq
- LVTX Nasdaq
- Market Cap
- CLGN 33.8M
- LVTX 40.0M
- IPO Year
- CLGN N/A
- LVTX 2021
- Fundamental
- Price
- CLGN $2.11
- LVTX $1.64
- Analyst Decision
- CLGN Strong Buy
- LVTX Hold
- Analyst Count
- CLGN 2
- LVTX 4
- Target Price
- CLGN $11.50
- LVTX $1.58
- AVG Volume (30 Days)
- CLGN 20.8K
- LVTX 131.8K
- Earning Date
- CLGN 11-26-2025
- LVTX 11-06-2025
- Dividend Yield
- CLGN N/A
- LVTX N/A
- EPS Growth
- CLGN N/A
- LVTX N/A
- EPS
- CLGN N/A
- LVTX N/A
- Revenue
- CLGN $2,475,000.00
- LVTX $4,990,000.00
- Revenue This Year
- CLGN $1,617.28
- LVTX N/A
- Revenue Next Year
- CLGN $83.54
- LVTX N/A
- P/E Ratio
- CLGN N/A
- LVTX N/A
- Revenue Growth
- CLGN 280.77
- LVTX N/A
- 52 Week Low
- CLGN $1.31
- LVTX $0.85
- 52 Week High
- CLGN $4.98
- LVTX $2.00
- Technical
- Relative Strength Index (RSI)
- CLGN 52.69
- LVTX 62.46
- Support Level
- CLGN $1.96
- LVTX $1.60
- Resistance Level
- CLGN $2.24
- LVTX $1.83
- Average True Range (ATR)
- CLGN 0.15
- LVTX 0.07
- MACD
- CLGN 0.03
- LVTX 0.01
- Stochastic Oscillator
- CLGN 95.00
- LVTX 65.28
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.